Who Paid My Doc
A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu
Research payments
$3,715,389
Through program year 2025, $3,715,389 in research payments was reported against A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu, across 786 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $543,841 | 396 |
| 2024 | Research | $2,938,075 | 341 |
| 2023 | Research | $233,474 | 49 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Hareshkumar Boghara Desoto, TX Named on 97 payments
- Aziz Shaibani Houston, TX Named on 84 payments
- Thomas Schnitzer Chicago, IL Named on 61 payments
- Joseph Caporusso McAllen, TX Named on 60 payments
- Harpaul Gill Houston, TX Named on 56 payments
- Dunia Hernandez Hollywood, FL Named on 54 payments
- Nazia Rahman Cleveland, OH Named on 39 payments
- Mark Kutner Miami, FL Named on 35 payments
- Deborah Burke Saint Petersburg, FL Named on 25 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.